SAB Biotherapeutics, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. SAB is a clinical-stage biopharmaceutical company developing human polyclonal antibodies. Its lead candidate, SAB-142, is being studied for type 1 diabetes (T1D); the company has no commercially approved products.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Grant revenue | $0.945 million | $0.581 million |
| Research and development expense | $8.146 million | $4.536 million |
| General and administrative expense | $4.189 million | $3.447 million |
| Operating loss | $11.391 million | $7.402 million |
| Net loss | $5.026 million | $7.354 million |
| Operating cash used | $10.750 million | $1.606 million |
- Revenue grew 62.5%, but remained grant-based. The company reported no product sales.
- R&D expense increased 79.6%; G&A increased 21.5%. The filing cites higher outside laboratory services, salaries and benefits, clinical trial activity, facility costs, and a $0.932 million out-of-period leasehold-improvement amortization adjustment in R&D.
- Net loss narrowed despite a larger operating loss, primarily because the company recorded a $5.468 million noncash gain from the change in fair value of warrant liabilities. Other income included a $0.475 million Australian R&D tax credit. These items are not equivalent to recurring operating improvement.
- Basic and diluted loss per share was $0.54, compared with $1.46 in Q1 2023. Weighted-average shares were 9.242 million versus 5.040 million; the 1-for-10 reverse stock split effective January 5, 2024 is reflected in share data.
- At March 31, cash and cash equivalents were $14.034 million and investments were approximately $31.258 million, totaling approximately $45.3 million in cash, cash equivalents and investments. Cash and equivalents were $56.566 million at year-end 2023. The quarter’s $42.532 million cash decline included $31.230 million of investment-security purchases, as well as operating cash use.
- Total assets were $71.371 million; stockholders’ equity was $52.822 million. Current assets of $46.951 million exceeded current liabilities of $8.305 million.
- Notes payable totaled $0.835 million, including an approximately $0.542 million 8% convertible note due September 30, 2024, and insurance financing. Finance lease liabilities were $3.518 million and operating lease liabilities were $1.097 million. Warrant liabilities were $6.306 million and are separate from borrowings.
Changes, outlook and risks
- Management says existing resources should cover operating cash needs for the 12 months following the report date, but expects continued losses and says additional capital will be needed for longer-term plans. Financing may not be available on acceptable terms; a shortfall could force the company to reduce or discontinue programs or take other restructuring actions.
- Management expects R&D costs to continue rising as it advances product candidates, and anticipates higher G&A costs to support operations and public-company obligations.
- Management reported that the Phase 1 SAB-142 trial began in November 2023. It anticipated Phase 1 topline results by the end of 2024 and a Phase 2 proof-of-concept/dose-range-finding study beginning in early 2025, with topline results expected at the end of 2026. These are forward-looking targets, not guarantees.
- In an April 16, 2024 update, the company said the third SAB-142 cohort had been enrolled and dosed, with no observed serum sickness at that point. The company also announced an INNODIA partnership in April. SAB-176 is expected to be evaluated in a Navy Medical Research Command safety and tolerability study with Henry Jackson Foundation funding.
- The $0.945 million Q1 grant revenue related to residual closeout activities under the terminated DoD JPEO contract. Management expects lower future revenue following termination; it says the T1D program is independently financed while it explores partnerships, co-development and licensing.
- The company disclosed ineffective disclosure controls as of March 31, 2024, citing a material weakness involving insufficient documentation of formal financial-reporting processes and procedures. Remediation efforts include a third-party risk assessment and a contract-management platform.
- Clinical, regulatory, financing, intellectual-property and commercialization risks remain significant. The filing reports no material litigation and no material change to the risk factors in the 2023 Form 10-K.
Important facts for investors to verify
- Whether cash, investments and any subsequent financing support the company’s stated runway, particularly as operating cash use rose year over year.
- Progress against SAB-142 trial milestones, including safety, biological activity, Phase 1 topline timing and plans for later-stage trials.
- How much future grant revenue, if any, is available after the DoD contract termination, and whether partnership or licensing opportunities emerge.
- The nature and resolution of the $0.932 million out-of-period amortization adjustment and the company’s plans to remediate its material weakness in financial-reporting controls.
- Potential dilution and contingent cash exposure associated with outstanding preferred warrants, including their terms and fair-value estimates.